This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

The Provenge Anchor Is Sinking Dendreon

SEATTLE ( TheStreet) -- Dendreon (DNDN) troubles, already substantial, just got so much worse.

Sales of the prostate cancer therapy Provenge fell short of the Street's second quarter expectations. The company now says Provenge sales will no longer grow year over year, as expected. Lastly, Dendreon's CFO Greg Schiffman announced his exit from the company at the end of the year.

The deluge of bad news, delivered during Dendreon's second-quarter earnings announcement Thursday night, is sure to raise even more concerns about the company's viability.

Dendreon shares closed Thursday down 1.5 percent to $4.59 but fell another 12 percent to $4.09 in after-hours trading.

Provenge sales in the June quarter totaled $73.3 million, or 8 percent quarter-over-quarter growth, versus Street consensus of $75 million, or 11 percent growth.

Based on patient enrollment trends this summer, Dendreon now say it doesn't expect Provenge sales growth to increase enough to meet its guidance of sales growth for the full year. Provenge use is being negatively impacted by competing prostate cancer drugs marketed by Johnson & Johnson (JNJ - Get Report) and Medivation (MDVN - Get Report), respectively.

For the first six months of the year, Provenge sales totaled $141 million and the Dendreon would have needed sales of $184 million in the third and fourth quarters. Thursday, the company said such sales growth is unlikely.

If there's any consolation to the disappointing retreat in Provenge guidance, it's that the Street didn't believe the company anyway, already expecting year over year sales to fall by 3 percent.

Dendreon ended the second quarter with $280.6 million in cash. Looming ahead is $545 million in convertible debt due in 2016.

Net loss in the second quarter was $68.8 million, or 45 cents per share, compared to a net loss of $96.1 million, or 65 cents per share, for the same period in 2012.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
DNDN $0.06 -6.02%
JNJ $100.58 0.00%
MDVN $126.62 0.00%
AAPL $132.65 0.00%
FB $81.91 0.00%

Markets

DOW 18,037.97 -42.17 -0.23%
S&P 500 2,108.92 -8.77 -0.41%
NASDAQ 5,060.2460 -31.8390 -0.63%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs